Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenin-25 for Glucose Homeostasis Post-RYGB
NCT02204813Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xenin in type 2 diabetes mellitus (T2DM), sponsored by Washington University School of Medicine. Primary endpoint: Insulin secretion rates at 5.5 hours. Started Jul 2014; status: completed.
02
Drugs
xenin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02204813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204813.